ImmunID Acquires Multi-Territory Key Patents for Proprietary Immunoassays

ImmunID Acquires Multi-Territory Key Patents for Proprietary Immunoassays

ImmunID, a company committed to finding breakthrough ways to personalize immunotherapy, recently acquired key patents in the following territories: United States, Canada, Europe, and Japan. These patents cover the company’s proprietary ImmunTraCkeR® and ImmunIG® assays, which help evaluate patients’ immune system. The two patent families (WO2005056828 and WO2009095567) cover the multi-N-plex® Polymerase Chain Reaction (PCR) technology behind the two assays. In previous studies, ImmunTraCkeR® showed the ability to predict patients’ response to immunotherapy, and is currently undergoing more tests to validate these findings.

“The immune system plays a fundamental role in diseases, which is why monitoring it is essential. As a pioneer in the field of immune molecular diagnostics for a decade, ImmunID has filed multiple patent applications covering clinical applications of its immune assays in immunotherapy, cancer and infections,” said Nicolas Pasqual, Chief Scientific Officer, and Sebastien Weisbuch, Chief Operating Officer, both co-founders of ImmunID.

“Our IP strategy focuses on ring-fencing the technology of our assays while securing the emerging clinical value. This combination creates the commercial value crucial to attract high quality investors and the funds needed to allow further validation and identification of new clinical utility for our assays,” added Bernhard Sixt, ImmunID’s Chairman and Chief Executive Officer.

To learn more about ImmunID, visit the company’s official website at

In an earlier report on immunoassays, Dr. John X.J. Zhang, PhD and his team of bioengineers from the Thayer School of Engineering at the private Ivy League research university Dartmouth College in Hanover, New Hampshire have demonstrated a novel system in which nano-engineered particles are coupled with microfluidic chips in order to capture and manipulate circulating tumor cells (CTCs).

This ability to quantify rare tumor markers will enable oncologists to make more precise prognoses and to select the most appropriate therapies for a particular case. The microscale immunoassays can also be further interfaced with fluorescent microscopy to yield cancer cell imaging.